Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abiraterone acetate - Johnson & Johnson

Next Previous
Drug Profile

Abiraterone acetate - Johnson & Johnson

Alternative Names: Abirateron-acetate-fine-particles; Aviraterone acetate; CB-7630; JNJ-212082; Zaitiga; Zaytiga; Zitiga; Zytiga

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Institute of Cancer Research
  • Developer All Ireland Cooperative Oncology Research Group; Assistance Publique Hopitaux de Paris; Cancer Research UK; Cougar Biotechnology; Instituto do Cancer do Estado de Sao Paulo; Janssen Research & Development; Johnson & Johnson; UNICANCER
  • Class Androstenols; Antiandrogens; Antineoplastics; Phenanthrenes; Pyridines; Small molecules
  • Mechanism of Action CYP17A1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Breast cancer; Ovarian cancer
  • No development reported Congenital adrenal hyperplasia

Most Recent Events

  • 02 Dec 2024 Johnson & Johnson completes a phase II IMAAGEN trial for Prostate cancer in the US (PO) (NCT01314118)
  • 03 Jan 2024 No development reported - Phase-III for Prostate cancer (Combination therapy, First-line therapy, Hormone refractory, Metastatic disease) in Italy (PO) (NCT02257736) (EudraCT2014-001718-25)
  • 02 Jun 2023 Updated efficacy data from the phase III PEACE-1 trial in in Prostate cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top